Serum alpha1-antitrypsin (A1AT) concentrations were determined by trypsin inhibitory capacity, rocket immunoelectrophoresis and single immunodiffusion in histologically proved 250 cases of hepatocellular carcinoma, 16 cholangiocarcinoma, 17 liver metastasis, 100 benign hepatic "space occupying lesions", 50 hepatitis, and 50 cirrhosis. A1AT﹥157 u or 420 mg / dl suggested malignant hepatoma. A1AT positive rates of the three methods were 58.4%, 65.9% and 66.2% respectively in malignant hepatoma, and only 11.9%, 6.3% and 7.5% in benign liver diseases.
There was no correlation between A1AT and A1FP. The serum A1AT concentrations of the 3 methods ranged 164.43 ± 53.68u, 438.01 ± 117.35 mg / dl and 436.93 ± 121.55 mg/dl respectively, and the positive rates of A1AT were 60.0%, 70.2% and 71.5% in 90 cases with AFP-negative primary liver cancer. The main factors affecting A1AT levels were the clinical stage of primary liver cancer, tumor size tumor capsule and tumor thrombus. In addition, A1AT assay may predict the resectability of this cancer and appraise the operative effect.